Carisma Therapeutics Inc. — Revenue by Fiscal Year
12 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/16f108fc-be41-4bb3-a897-916c3cfa4705/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2024 | $19.6M | 2024-01-01 – 2024-12-31 | evidence 0001628280-25-015673 |
| FY 2023 | $14.9M | 2023-01-01 – 2023-12-31 | evidence 0001485003-24-000005 |
| FY 2022 | $9.8M | 2022-01-01 – 2022-12-31 | evidence 0001485003-24-000005 |
| FY 2021 | $26.5M | 2021-01-01 – 2021-12-31 | evidence 0001485003-22-000033 |
| FY 2020 | $11.2M | 2020-01-01 – 2020-12-31 | evidence 0001485003-21-000044 |
| FY 2019 | $0 | 2019-01-01 – 2019-12-31 | evidence 0001485003-20-000038 |
| FY 2018 | $0 | 2018-01-01 – 2018-12-31 | evidence 0001485003-19-000015 |
| FY 2017 | $425.0k | 2017-01-01 – 2017-12-31 | evidence 0001485003-19-000015 |
| FY 2016 | $30.0M | 2016-01-01 – 2016-12-31 | evidence 0001485003-19-000015 |
| FY 2015 | $990.0k | 2015-01-01 – 2015-12-31 | evidence 0001485003-16-000068 |
| FY 2014 | $2.2M | 2014-01-01 – 2014-12-31 | evidence 0001485003-16-000068 |
| FY 2013 | $1.3M | 2013-01-01 – 2013-12-31 | evidence 0001485003-16-000068 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Carisma Therapeutics Inc. — all facts · Net Income · Operating Income